Home
NUVL
NUVL News

Latest Nuvalent Inc. (NUVL) News on July 2, 2025

Nuvalent price target raised to $140 from $125 at Leerink

TipRanks

7 days ago

Nuvalent price target raised to $140 from $125 at Leerink

Nuvalent price target raised to $130 from $110 at H.C. Wainwright

TipRanks

7 days ago

Nuvalent price target raised to $130 from $110 at H.C. Wainwright

MT Newswires

8 days ago

Nuvalent Reports Positive Data From Phase 1/2 Trial of Zidesamtinib in Lung Cancer

Chasing rivals, Nuvalent to seek approval of targeted lung cancer drug

BioPharma Dive

8 days ago

Chasing rivals, Nuvalent to seek approval of targeted lung cancer drug

Nuvalent Announces Positive Pivotal Data from ARROS-1 Clinical Trial of Zidesamtinib for TKI Pre-treated Patients with Advanced ROS1-positive NSCLC

PR Newswire

8 days ago

Nuvalent Announces Positive Pivotal Data from ARROS-1 Clinical Trial of Zidesamtinib for TKI Pre-treated Patients with Advanced ROS1-positive NSCLC

Nuvalent Announces Timing of Pivotal Data for TKI Pre-treated Patients with Advanced ROS1-positive NSCLC from ARROS-1 Clinical Trial of Zidesamtinib

PR Newswire

8 days ago

Nuvalent Announces Timing of Pivotal Data for TKI Pre-treated Patients with Advanced ROS1-positive NSCLC from ARROS-1 Clinical Trial of Zidesamtinib

Nuvalent Appoints Christy Oliger to Board of Directors

PR Newswire

13 days ago

Nuvalent Appoints Christy Oliger to Board of Directors

MT Newswires

14 days ago

Nuvalent Insider Sold Shares Worth $2,077,093, According to a Recent SEC Filing

Nuvalent Outlines Recent Pipeline and Business Progress, Reiterates Key Anticipated Milestones, and Reports First Quarter 2025 Financial Results

PR Newswire

2 months ago

Nuvalent Outlines Recent Pipeline and Business Progress, Reiterates Key Anticipated Milestones, and Reports First Quarter 2025 Financial Results

Nuvalent Announces Publication in Molecular Cancer Therapeutics Reinforcing Rational Molecular Design of Zidesamtinib as a Novel ROS1-Selective Inhibitor

PR Newswire

2 months ago

Nuvalent Announces Publication in Molecular Cancer Therapeutics Reinforcing Rational Molecular Design of Zidesamtinib as a Novel ROS1-Selective Inhibitor

Nuvalent, Inc. (NUVL): Among Takeover Rumors Hedge Funds Are Buying

Insider Monkey

2 months ago

Nuvalent, Inc. (NUVL): Among Takeover Rumors Hedge Funds Are Buying

Is Nuvalent, Inc. (NUVL) Among the Best Guru Stocks to Buy According to Wall Street Analysts?

Insider Monkey

2 months ago

Is Nuvalent, Inc. (NUVL) Among the Best Guru Stocks to Buy According to Wall Street Analysts?

Nuvalent to Present Trial in Progress Posters for the ALKAZAR Trial of Neladalkib and HEROEX-1 Trial of NVL-330 at the 2025 American Society of Clinical Oncology Annual Meeting

PR Newswire

2 months ago

Nuvalent to Present Trial in Progress Posters for the ALKAZAR Trial of Neladalkib and HEROEX-1 Trial of NVL-330 at the 2025 American Society of Clinical Oncology Annual Meeting

Is Nuvalent (NUVL) the Best Debt Free Mid Cap Stock to Buy Now?

Insider Monkey

3 months ago

Is Nuvalent (NUVL) the Best Debt Free Mid Cap Stock to Buy Now?

Nuvalent to Participate in the Stifel 2025 Virtual Targeted Oncology Forum

PR Newswire

3 months ago

Nuvalent to Participate in the Stifel 2025 Virtual Targeted Oncology Forum

Why Nuvalent (NUVL) Is Among the Best Mid Cap Biotech Stocks to Buy

Insider Monkey

3 months ago

Why Nuvalent (NUVL) Is Among the Best Mid Cap Biotech Stocks to Buy

Nuvalent to Present New Preclinical Data on ALK-Selective Inhibitor, Neladalkib, and ROS1-Selective Inhibitor, Zidesamtinib, at AACR Annual Meeting 2025

PR Newswire

3 months ago

Nuvalent to Present New Preclinical Data on ALK-Selective Inhibitor, Neladalkib, and ROS1-Selective Inhibitor, Zidesamtinib, at AACR Annual Meeting 2025

MT Newswires

3 months ago

Nuvalent Insider Sold Shares Worth $2,048,562, According to a Recent SEC Filing

MT Newswires

4 months ago

UBS Upgrades Nuvalent to Buy From Neutral, Maintains $100 Price Target

MT Newswires

4 months ago

Nuvalent Insider Sold Shares Worth $2,443,578, According to a Recent SEC Filing

Nuvalent to Participate in Upcoming March Investor Conferences

PR Newswire

4 months ago

Nuvalent to Participate in Upcoming March Investor Conferences

MT Newswires

4 months ago

Nuvalent's Q4 Net Loss Widens

Nuvalent Outlines Pipeline and Business Progress, Reiterates Key Anticipated Milestones, and Reports Fourth Quarter and Full Year 2024 Financial Results

PR Newswire

4 months ago

Nuvalent Outlines Pipeline and Business Progress, Reiterates Key Anticipated Milestones, and Reports Fourth Quarter and Full Year 2024 Financial Results

Why Insiders Are Selling Nuvalent, Inc. (NUVL) Recently

Insider Monkey

5 months ago

Why Insiders Are Selling Nuvalent, Inc. (NUVL) Recently

Nuvalent (NASDAQ:NUVL) Is In A Good Position To Deliver On Growth Plans

Simply Wall St.

5 months ago

Nuvalent (NASDAQ:NUVL) Is In A Good Position To Deliver On Growth Plans

Is Nuvalent, Inc. (NUVL) Among Billionaire Joseph Edelman’s Long-Term Stock Picks?

Insider Monkey

5 months ago

Is Nuvalent, Inc. (NUVL) Among Billionaire Joseph Edelman’s Long-Term Stock Picks?

Nuvalent Details Strategy to Seek First Potential Approval in 2026 and Outlines Key Anticipated 2025 Milestones

PR Newswire

6 months ago

Nuvalent Details Strategy to Seek First Potential Approval in 2026 and Outlines Key Anticipated 2025 Milestones

MT Newswires

6 months ago

Nuvalent Insider Sold Shares Worth $320,009, According to a Recent SEC Filing

American Air upgraded, Nordstrom downgraded: Wall Street's top analyst calls

The Fly

6 months ago

American Air upgraded, Nordstrom downgraded: Wall Street's top analyst calls

MT Newswires

6 months ago

HC Wainwright Initiates Nuvalent at Buy With $110 Price Target

Nuvalent to Present at the 43rd Annual J.P. Morgan Healthcare Conference

PR Newswire

6 months ago

Nuvalent to Present at the 43rd Annual J.P. Morgan Healthcare Conference

MT Newswires

6 months ago

Nuvalent Insider Sold Shares Worth $2,338,436, According to a Recent SEC Filing

Nuvalent Appoints Grant Bogle to Board of Directors

PR Newswire

7 months ago

Nuvalent Appoints Grant Bogle to Board of Directors

Nuvalent to Participate in the Piper Sandler 36th Annual Healthcare Conference

PR Newswire

7 months ago

Nuvalent to Participate in the Piper Sandler 36th Annual Healthcare Conference

MT Newswires

8 months ago

Nuvalent's Q3 Net Loss Widens

Nuvalent Highlights Corporate and Pipeline Achievements, Reiterates Key Anticipated Milestones, and Reports Third Quarter 2024 Financial Results

PR Newswire

8 months ago

Nuvalent Highlights Corporate and Pipeline Achievements, Reiterates Key Anticipated Milestones, and Reports Third Quarter 2024 Financial Results

MT Newswires

8 months ago

Nuvalent Insider Sold Shares Worth $442,980, According to a Recent SEC Filing

MT Newswires

8 months ago

UBS Initiates Nuvalent With Neutral Rating, $100 Price Target

MT Newswires

9 months ago

Nuvalent Insider Sold Shares Worth $508,718, According to a Recent SEC Filing

Biotech Stock Roundup: GILD, NUVL Stocks Surge on Study Data, MRNA Down on Updates

Zacks

9 months ago

Biotech Stock Roundup: GILD, NUVL Stocks Surge on Study Data, MRNA Down on Updates

MT Newswires

9 months ago

Nuvalent Insider Sold Shares Worth $3,244,140, According to a Recent SEC Filing

MT Newswires

9 months ago

Nuvalent Raises $575 Million From Share Offering

Nuvalent Announces Closing of Upsized Public Offering of Common Stock

PR Newswire

9 months ago

Nuvalent Announces Closing of Upsized Public Offering of Common Stock

Nuvalent Stock Moves Up 20% in a Week: What's Driving the Rally?

Zacks

9 months ago

Nuvalent Stock Moves Up 20% in a Week: What's Driving the Rally?

Company News for Sep 17, 2024

Zacks

9 months ago

Company News for Sep 17, 2024

MT Newswires

10 months ago

Nuvalent Prices $500 Million Stock Offering

Nuvalent Announces Pricing of Upsized Public Offering of Common Stock

PR Newswire

10 months ago

Nuvalent Announces Pricing of Upsized Public Offering of Common Stock

Nuvalent Flies On 'Multibillion-Dollar' Potential, While Iteos Crashes On Patient Deaths

Investor's Business Daily

10 months ago

Nuvalent Flies On 'Multibillion-Dollar' Potential, While Iteos Crashes On Patient Deaths

MT Newswires

10 months ago

Sector Update: Health Care Stocks Advance in Afternoon Trading

MT Newswires

10 months ago

Top Midday Gainers

MT Newswires

10 months ago

Update: Nuvalent Shares Jump After Trials of Lung Cancer Drugs Show 'Favorable Tolerability'

Cancer Biotech Nuvalent’s Stock Jumps on Positive Data

Barrons.com

10 months ago

Cancer Biotech Nuvalent’s Stock Jumps on Positive Data

MT Newswires

10 months ago

Nuvalent Says 2 Potential Lung Cancer Drugs Show 'Favorable Tolerability'

MT Newswires

10 months ago

Sector Update: Health Care Stocks Flat to Higher Premarket Monday

MT Newswires

10 months ago

Sector Update: Health Care

MT Newswires

10 months ago

Nuvalent Launches $350 Million Common Stock Offering

MT Newswires

10 months ago

Wedbush Raises Price Target on Nuvalent to $115 From $99, Keeps Outperform Rating

Nuvalent Announces Public Offering of Common Stock

PR Newswire

10 months ago

Nuvalent Announces Public Offering of Common Stock

Nuvalent, Inc. (NUVL): Among Hedge Funds’ Top Biotech Stock Picks

Insider Monkey

10 months ago

Nuvalent, Inc. (NUVL): Among Hedge Funds’ Top Biotech Stock Picks

Nuvalent, Inc. (NUVL): Short Seller Sentiment is Bearish on This Cancer Stock

Insider Monkey

10 months ago

Nuvalent, Inc. (NUVL): Short Seller Sentiment is Bearish on This Cancer Stock

Nuvalent Highlights Presentation of Clinical Data at ESMO 2024 for Parallel Lead Programs for ROS1 and ALK-positive NSCLC and Accelerated Development Timelines

PR Newswire

10 months ago

Nuvalent Highlights Presentation of Clinical Data at ESMO 2024 for Parallel Lead Programs for ROS1 and ALK-positive NSCLC and Accelerated Development Timelines

Nuvalent Announces Publication in Cancer Discovery Detailing Design and Characterization of ALK-selective inhibitor NVL-655

PR Newswire

10 months ago

Nuvalent Announces Publication in Cancer Discovery Detailing Design and Characterization of ALK-selective inhibitor NVL-655

Updated Data for Nuvalent's ALK-Selective Inhibitor, NVL-655, and ROS1-Selective Inhibitor, Zidesamtinib, Continue to Support Potential Best-in-Class Profiles

PR Newswire

10 months ago

Updated Data for Nuvalent's ALK-Selective Inhibitor, NVL-655, and ROS1-Selective Inhibitor, Zidesamtinib, Continue to Support Potential Best-in-Class Profiles

Here's Why We're Not Too Worried About Nuvalent's (NASDAQ:NUVL) Cash Burn Situation

Simply Wall St.

10 months ago

Here's Why We're Not Too Worried About Nuvalent's (NASDAQ:NUVL) Cash Burn Situation

Nuvalent to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference

PR Newswire

10 months ago

Nuvalent to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference

MT Newswires

10 months ago

Barclays Initiates Nuvalent at Overweight

MT Newswires

10 months ago

Nuvalent Insider Sold Shares Worth $935,440, According to a Recent SEC Filing

MT Newswires

10 months ago

Nuvalent Insider Sold Shares Worth $893,340, According to a Recent SEC Filing

MT Newswires

a year ago

Nuvalent's Q2 Net Loss Widens

Nuvalent Highlights Pipeline Progress, Reiterates Key Anticipated Milestones, and Reports Second Quarter 2024 Financial Results

PR Newswire

a year ago

Nuvalent Highlights Pipeline Progress, Reiterates Key Anticipated Milestones, and Reports Second Quarter 2024 Financial Results

MT Newswires

a year ago

Nuvalent Insider Sold Shares Worth $795,074, According to a Recent SEC Filing

Nuvalent doses first subject in Phase Ia/Ib trial of lung cancer treatment

Clinical Trials Arena

a year ago

Nuvalent doses first subject in Phase Ia/Ib trial of lung cancer treatment

Nuvalent Announces First Patient Dosed in HEROEX-1 Phase 1a/1b Clinical Trial of NVL-330, its Novel HER2-selective Inhibitor

PR Newswire

a year ago

Nuvalent Announces First Patient Dosed in HEROEX-1 Phase 1a/1b Clinical Trial of NVL-330, its Novel HER2-selective Inhibitor

MT Newswires

a year ago

Nuvalent Insider Sold Shares Worth $403,621, According to a Recent SEC Filing

Nuvalent to Present Updated Data for ROS1-Selective Inhibitor, Zidesamtinib, and ALK-Selective Inhibitor, NVL-655, at the ESMO Congress 2024

PR Newswire

a year ago

Nuvalent to Present Updated Data for ROS1-Selective Inhibitor, Zidesamtinib, and ALK-Selective Inhibitor, NVL-655, at the ESMO Congress 2024

MT Newswires

a year ago

Nuvalent Names Henry Pelish Chief Scientific Officer; Shares Rise

Nuvalent Announces Promotion of Henry Pelish, Ph.D. to Chief Scientific Officer

PR Newswire

a year ago

Nuvalent Announces Promotion of Henry Pelish, Ph.D. to Chief Scientific Officer

MT Newswires

a year ago

Stifel Adjusts Price Target on Nuvalent to $115 From $103, Maintains Buy Rating

MT Newswires

a year ago

Nuvalent Insider Sold Shares Worth $643,213, According to a Recent SEC Filing

Nuvalent to Participate in the 2024 Jefferies Global Healthcare Conference

PR Newswire

a year ago

Nuvalent to Participate in the 2024 Jefferies Global Healthcare Conference

MT Newswires

a year ago

Nuvalent Insider Sold Shares Worth $345,450, According to a Recent SEC Filing

FDA grants breakthrough therapy status for Nuvalent’s NVL-655

Pharmaceutical Technology

a year ago

FDA grants breakthrough therapy status for Nuvalent’s NVL-655

MT Newswires

a year ago

Nuvalent Gets Breakthrough Therapy Designation for Lung Cancer Treatment Candidate

Nuvalent Receives U.S. FDA Breakthrough Therapy Designation for NVL-655

PR Newswire

a year ago

Nuvalent Receives U.S. FDA Breakthrough Therapy Designation for NVL-655

MT Newswires

a year ago

Nuvalent Q1 Net Loss Widens

Nuvalent Highlights Pipeline Progress, Reiterates Key Anticipated Milestones, and Reports First Quarter 2024 Financial Results

PR Newswire

a year ago

Nuvalent Highlights Pipeline Progress, Reiterates Key Anticipated Milestones, and Reports First Quarter 2024 Financial Results

MT Newswires

a year ago

Nuvalent Insider Sold Shares Worth $2,605,525, According to a Recent SEC Filing

Why Earnings Season Could Be Great for Nuvalent (NUVL)

Zacks

a year ago

Why Earnings Season Could Be Great for Nuvalent (NUVL)

MT Newswires

a year ago

Nuvalent Insider Sold Shares Worth $2,666,555, According to a Recent SEC Filing

Nuvalent Presents New Preclinical Data Supporting Profiles of HER2-Selective Inhibitor, NVL-330, and ROS1-Selective Inhibitor, Zidesamtinib, at AACR Annual Meeting 2024

PR Newswire

a year ago

Nuvalent Presents New Preclinical Data Supporting Profiles of HER2-Selective Inhibitor, NVL-330, and ROS1-Selective Inhibitor, Zidesamtinib, at AACR Annual Meeting 2024

Chief Legal Officer Deborah Miller Sells 3,000 Shares of Nuvalent Inc (NUVL)

GuruFocus.com

a year ago

Chief Legal Officer Deborah Miller Sells 3,000 Shares of Nuvalent Inc (NUVL)

ARS Pharmaceuticals, Nuvalent, and More Stocks See Action From Activist Investors

Barrons.com

a year ago

ARS Pharmaceuticals, Nuvalent, and More Stocks See Action From Activist Investors

Chief Legal Officer Deborah Miller Sells 22,000 Shares of Nuvalent Inc (NUVL)

GuruFocus.com

a year ago

Chief Legal Officer Deborah Miller Sells 22,000 Shares of Nuvalent Inc (NUVL)

Chief Development Officer Darlene Noci Sells 20,000 Shares of Nuvalent Inc (NUVL)

GuruFocus.com

a year ago

Chief Development Officer Darlene Noci Sells 20,000 Shares of Nuvalent Inc (NUVL)

Companies Like Nuvalent (NASDAQ:NUVL) Can Afford To Invest In Growth

Simply Wall St.

a year ago

Companies Like Nuvalent (NASDAQ:NUVL) Can Afford To Invest In Growth

Director Emily Conley Sells 13,333 Shares of Nuvalent Inc (NUVL)

GuruFocus.com

a year ago

Director Emily Conley Sells 13,333 Shares of Nuvalent Inc (NUVL)

Nuvalent to Present New Preclinical Data on HER2-Selective Inhibitor, NVL-330, and ROS1-Selective Inhibitor, zidesamtinib, at AACR Annual Meeting 2024

PR Newswire

a year ago

Nuvalent to Present New Preclinical Data on HER2-Selective Inhibitor, NVL-330, and ROS1-Selective Inhibitor, zidesamtinib, at AACR Annual Meeting 2024

GuruFocus.com

a year ago

Nuvalent Inc (NUVL) Reports Full Year and Q4 2023 Financial Results with Strong Cash Position ...

Nuvalent Highlights Pipeline Progress, Reiterates Key Anticipated Milestones and Reports Fourth Quarter and Full Year 2023 Financial Results

PR Newswire

a year ago

Nuvalent Highlights Pipeline Progress, Reiterates Key Anticipated Milestones and Reports Fourth Quarter and Full Year 2023 Financial Results

Nuvalent Receives U.S. FDA Breakthrough Therapy Designation for NVL-520

PR Newswire

a year ago

Nuvalent Receives U.S. FDA Breakthrough Therapy Designation for NVL-520

Share on Social Networks: